Theravance Biopharma Inc (TBPH) financials · $861.5M cap
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Theravance Biopharma Inc (TBPH) $861.5M cap.
| Line | Q2 2026 | Q1 2026 |
|---|---|---|
| Revenue | $20.7M | $17.7M |
| Operating Income | -$8.28M | -$9.48M |
| Net Income | -$5.90M | -$4.93M |
| EPS (Diluted) | -$0.11 | -$0.10 |
| Line | Q2 2026 | Q1 2026 |
|---|---|---|
| Total Assets | $469.8M | $472.3M |
| Current Assets | $416.7M | $417.6M |
| Cash & Equivalents | $219.8M | $288.1M |
| PP&E | $5.17M | $5.54M |
| Total Liabilities | $180.1M† | $181.7M† |
| Current Liabilities | $30.8M | $31.8M |
| Shareholders' Equity | $289.7M | $290.6M |
| Retained Earnings | -$870.5M | -$864.6M |
† Total Liabilities: Derived: total assets minus shareholders’ equity (stored total liabilities equalled total assets, i.e. the liabilities-and-equity total).
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | $238.5M | -$11.5M |
| CapEx | $42.0K | $332.0K |
| Investing Cash Flow | -$105.3M | $12.3M |
| Financing Cash Flow | -$3.25M | -$2.50M |
| Net Change in Cash | $130.0M | -$1.75M |
| Free Cash Flow | $238.5M | -$11.9M |
FAQ
What is TBPH P/E and revenue?
Theravance Biopharma Inc (TBPH) $861.5M cap.
What is TBPH revenue?
Theravance Biopharma Inc last cached revenue is $20.7M (Q2 2026).
Is TBPH profitable?
Theravance Biopharma Inc last cached net income is -$5.90M (Q2 2026).
What are TBPH total assets?
Theravance Biopharma Inc last cached total assets are $469.8M (Q2 2026).
What is TBPH free cash flow?
Theravance Biopharma Inc last cached free cash flow is $238.5M (FY2025).
Not investment advice. Cached statements, not a live tape.